BTIG Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $63
Vericel to Present at Multiple Upcoming Investor Conferences
Truist Financial Maintains Vericel(VCEL.US) With Buy Rating, Announces Target Price $61
Truist Financial Maintains Vericel(VCEL.US) With Buy Rating
Truist Securities Cuts Price Target on Vericel to $61 From $67, Keeps Buy Rating
A Quick Look at Today's Ratings for Vericel(VCEL.US), With a Forecast Between $60 to $72
Analysts Offer Insights on Healthcare Companies: Vericel (VCEL), Radnet (RDNT) and Universal Health (UHS)
Truist Financial Remains a Buy on Vericel (VCEL)
Vericel Analyst Ratings
Vericel's Growth Potential: Expanding MACI Franchise and Burn Care Innovations Drive Buy Rating
Earnings Call Summary | Vericel(VCEL.US) Q4 2024 Earnings Conference
Analysts Are Bullish on Top Healthcare Stocks: Vericel (VCEL), Astria Therapeutics (ATXS)
Vericel | 10-K: FY2024 Annual Report
Vericel Q4 Net Income, Revenue Increase; 2025 Revenue Growth Outlook Issued
Vericel | 8-K: Press Release of Vericel Corporation, “Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results”
Vericel Corporation Reports 20% Revenue Growth and 58% Adjusted EBITDA Increase for Full-Year 2024
Earnings Flash (VCEL) VERICEL CORPORATION Posts Q4 Revenue $75.4M, Vs. FactSet Est of $76.5M
Express News | Vericel Corp - 2025 Financial Guidance With Total Revenue Growth of 20% to 23% Reaffirmed
Press Release: Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
Express News | Vericel Q4 Adjusted Ebitda USD 29.9 Million Vs. IBES Estimate USD 29.4 Million